Zacks: Analysts Expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) to Post -$0.74 Earnings Per Share – Defense World

Posted by on May 10th, 2022
Brokerages forecast that TCR2 Therapeutics Inc. (NASDAQ:TCRRGet Rating) will report earnings per share of ($0.74) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for TCR2 Therapeutics’ earnings. The highest EPS estimate is ($0.68) and the lowest is ($0.79). TCR2 Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which suggests a negative year over year growth rate of 27.6%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that TCR2 Therapeutics will report full year earnings of ($2.95) per share for the current year, with EPS estimates ranging from ($3.31) to ($2.60). For the next fiscal year, analysts forecast that the company will report earnings of ($2.66) per share, with EPS estimates ranging from ($4.30) to ($1.33). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow TCR2 Therapeutics.
TCR2 Therapeutics (NASDAQ:TCRRGet Rating) last released its quarterly earnings results on Tuesday, March 22nd. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.01.

TCRR has been the subject of a number of recent research reports. HC Wainwright dropped their price target on shares of TCR2 Therapeutics from $25.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, January 13th. Piper Sandler reduced their price target on shares of TCR2 Therapeutics from $26.00 to $23.00 in a report on Tuesday, March 22nd. The Goldman Sachs Group lowered shares of TCR2 Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $28.00 to $5.00 in a research report on Wednesday, January 19th. Finally, Zacks Investment Research lowered shares of TCR2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 18th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $17.39.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Moors & Cabot Inc. purchased a new position in TCR2 Therapeutics during the 3rd quarter worth $25,000. Macquarie Group Ltd. bought a new stake in TCR2 Therapeutics in the 3rd quarter valued at about $30,000. Newman Dignan & Sheerar Inc. purchased a new stake in TCR2 Therapeutics in the 1st quarter worth approximately $30,000. Private Advisor Group LLC bought a new stake in TCR2 Therapeutics during the fourth quarter valued at $52,000. Finally, Guggenheim Capital LLC bought a new stake in shares of TCR2 Therapeutics during the 4th quarter valued at about $53,000. 82.99% of the stock is owned by institutional investors and hedge funds.
Shares of TCR2 Therapeutics stock traded up $0.18 during trading on Tuesday, hitting $2.38. 28,128 shares of the company’s stock traded hands, compared to its average volume of 603,626. TCR2 Therapeutics has a twelve month low of $2.10 and a twelve month high of $20.44. The company has a market cap of $91.74 million, a PE ratio of -0.89 and a beta of 2.22. The firm’s fifty day moving average price is $2.55 and its 200 day moving average price is $3.91.
TCR2 Therapeutics Company Profile (Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
See Also

Get a free copy of the Zacks research report on TCR2 Therapeutics (TCRR)
For more information about research offerings from Zacks Investment Research, visit
Earnings History and Estimates for TCR2 Therapeutics (NASDAQ:TCRR)
Receive News & Ratings for TCR2 Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TCR2 Therapeutics and related companies with’s FREE daily email newsletter.
iSun, Inc. (NASDAQ:ISUN) Expected to Post Earnings of -$0.07 Per Share
Research Analysts’ Weekly Ratings Updates for Lennox International (LII)

Read More


Related posts

Leave a Reply

Your email address will not be published.